WO2004104168A3 - Mrbs as modifiers of the rb pathway and methods of use - Google Patents

Mrbs as modifiers of the rb pathway and methods of use Download PDF

Info

Publication number
WO2004104168A3
WO2004104168A3 PCT/US2004/014964 US2004014964W WO2004104168A3 WO 2004104168 A3 WO2004104168 A3 WO 2004104168A3 US 2004014964 W US2004014964 W US 2004014964W WO 2004104168 A3 WO2004104168 A3 WO 2004104168A3
Authority
WO
WIPO (PCT)
Prior art keywords
pathway
methods
mrbs
modifiers
mrb
Prior art date
Application number
PCT/US2004/014964
Other languages
French (fr)
Other versions
WO2004104168A2 (en
Inventor
Helen Francis-Lang
Kyle Andrew Edgar
Joanne I Adamkewicz
Kim Lickteig
Original Assignee
Exelixis Inc
Helen Francis-Lang
Kyle Andrew Edgar
Joanne I Adamkewicz
Kim Lickteig
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc, Helen Francis-Lang, Kyle Andrew Edgar, Joanne I Adamkewicz, Kim Lickteig filed Critical Exelixis Inc
Publication of WO2004104168A2 publication Critical patent/WO2004104168A2/en
Publication of WO2004104168A3 publication Critical patent/WO2004104168A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4736—Retinoblastoma protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Human MRB genes are identified as modulators of the RB pathway, and thus are therapeutic targets for disorders associated with defective RB function. Methods for identifying modulators of RB, comprising screening for agents that modulate the activity of MRB are provided.
PCT/US2004/014964 2003-05-14 2004-05-13 Mrbs as modifiers of the rb pathway and methods of use WO2004104168A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47067503P 2003-05-14 2003-05-14
US60/470,675 2003-05-14

Publications (2)

Publication Number Publication Date
WO2004104168A2 WO2004104168A2 (en) 2004-12-02
WO2004104168A3 true WO2004104168A3 (en) 2005-08-04

Family

ID=33476735

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/014964 WO2004104168A2 (en) 2003-05-14 2004-05-13 Mrbs as modifiers of the rb pathway and methods of use

Country Status (1)

Country Link
WO (1) WO2004104168A2 (en)

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GUTIERREZ ET AL: "The retiniblastoma pathway in plant cell cycle and development.", CURR OPIN PLANT BIOL., vol. 1, 1998, pages 492 *
KUZIN ET AL: "Nitric oxide inteacts with the retinoblastoma pathway.", CURR.BIOL., vol. 10, 2000, pages 459 - 462 *
PRUITT ET AL: "Ras Inactivation of the retinoblastoma pathway.", J.BIOL.CHEM., vol. 275, 2000, pages 40916 *

Also Published As

Publication number Publication date
WO2004104168A2 (en) 2004-12-02

Similar Documents

Publication Publication Date Title
WO2002099138A3 (en) HS2STs AS MODIFIERS OF THE P53 PATHWAY AND METHODS OF USE
WO2002099074A3 (en) Slc7s as modifiers of the p53 pathway and methods of use
WO2003073823A3 (en) PDPK1s AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
WO2003014301A3 (en) Hprp4s as modifiers of the p53 pathway and methods of use
WO2005016287A3 (en) Prkwnks as modifiers of the rac pathway and methods of use
WO2003051905A3 (en) Taojiks as modifiers of the beta-catenin pathway and methods of use
WO2002099043A8 (en) P5CRS AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
WO2004024882A3 (en) FLJ20647s AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE
WO2004013309A3 (en) PAPSSs AS MODIFIERS OF THE AXIN PATHWAY AND METHODS OF USE
WO2003035831A3 (en) Lrrcaps as modifiers of the p53 pathway and methods of use
WO2004015072A3 (en) Mrbs as modifiers of the rb pathway and methods of use
WO2004005483A3 (en) ADCY3S AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE
WO2004015071A3 (en) CSNK1GS AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE
WO2005017123A3 (en) Mptens as modifiers of the pten pathway and methods of use
WO2004048541A3 (en) Cct6s as modifiers of the rb pathway and methods of use
WO2004065542A3 (en) MAT2As AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
WO2004048538A3 (en) Csnks as modifiers of the rac pathway and methods of use
WO2004104168A3 (en) Mrbs as modifiers of the rb pathway and methods of use
WO2004083389A3 (en) Mbcats as modifiers of the beta-catenin pathway and methods of use
WO2003074725A3 (en) MBCATs AS MODIFIERS OF THE BETA-CATENIN PATHWAY AND METHODS OF USE
WO2004061123A3 (en) Mbcats as modifiers of the beta-catenin pathway and methods of use
WO2004015069A3 (en) MP2153S AS MODIFIERS OF THE p21 OR p53 PATHWAY AND METHODS OF USE
WO2003052068A3 (en) Mbcats as modifiers of the beta-catenin pathway and methods of use
WO2003074677A3 (en) MCHKs AS MODIFIERS OF THE CHK PATHWAY AND METHODS OF USE
WO2003074673A3 (en) Lgals as modifiers of the chk pathway and methods of use

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase